A recent randomized, placebo-controlled, triple-blind study found that a proprietary ginseng extract called Farlong NotoGinseng supported cholesterol and blood pressure.
Photo © AdobeStock.com/Маргарита Медведева
A recent randomized, placebo-controlled, triple-blind study1 found that a proprietary ginseng extract called Farlong NotoGinseng from Farlong Pharmaceutical (Walnut, CA) supported cholesterol and blood pressure. In the study 95 health participants with normal to mild hypertension and hypercholesterolemia, were either given ginseng or placebo daily for 12 weeks. Lipid profile, blood pressure, and endothelial vasodilation parameters were assessed at baseline and weeks four, eight, and 12.
Results showed that subjects taking the ginseng extract saw a 4.33% reduction in low-density lipoprotein cholesterol (LDL-C) at week eight, and a 1.8% improvement in high-density lipoprotein cholesterol (HDL-C) at week 12. By contrast, subjects in the placebo group saw a non-significant 1.37% reduction in HDL-C at both eight and 12 weeks. Ginseng also improved systolic and diastolic blood pressure in subjects, by 0.94% and 0.16%, respectively, while subjects in the placebo group saw an increase in those measures. In total, 17.5% of subjects in the ginseng group experiences improvements in three cardiovascular disease risk factors (LDL-C, HDL-C, and systolic blood pressure), compared to 5% in the placebo group. The ginseng group also saw the highest proportion of subjects with borderline high levels of LDL-C at baseline to have a reduction in cardiovascular disease risk factors (42%). Overall, the extract was well tolerated and demonstrated a potential positive influence on cardiovascular disease risk.
Reference
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.